Drugs

Drug Development for Myalgic Encephalomyelitis and Chronic Fatigue Syndrome (ME and CFS)

FDA is planning a series of activities focused on drug development to treat the symptoms of Myalgic Encephalomyelitis and Chronic Fatigue Syndrome (ME and CFS) in order to explore:

  • The burden of disease that impacts the quality of life for ME and CFS patients;
  • The quantitative outcome measures or endpoints that determine if disease symptoms improve with intervention; and
  • How drug efficacy should be clinically tested based on these endpoints or measurements.

Please send correspondence regarding ME and CFS to ME-CFS-Meeting@fda.hhs.gov.

Activities

Please Note: The list of activities will be updated as each activity is announced.

 

Page Last Updated: 12/11/2014
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.